<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Pharm Rep</journal-id><journal-id journal-id-type="iso-abbrev">Med Pharm Rep</journal-id><journal-id journal-id-type="publisher-id">Med Pharm Rep</journal-id><journal-title-group><journal-title>Medicine and Pharmacy Reports</journal-title></journal-title-group><issn pub-type="ppub">2602-0807</issn><issn pub-type="epub">2668-0572</issn><publisher><publisher-name>Iuliu Hatieganu University of Medicine and Pharmacy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9387571</article-id><article-id pub-id-type="doi">10.15386/mpr-2120</article-id><article-id pub-id-type="publisher-id">cm-95-251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject><subj-group><subject>Oncology</subject></subj-group></subj-group></article-categories><title-group><article-title>Endoglin (CD105) as a putative prognostic biomarker for colorectal cancer: a systematic review</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Sur</surname><given-names>Daniel</given-names></name><xref rid="af1-cm-95-251" ref-type="aff">1</xref><xref rid="af2-cm-95-251" ref-type="aff">2</xref><xref rid="fn1-cm-95-251" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Havasi</surname><given-names>Andrei</given-names></name><xref rid="af1-cm-95-251" ref-type="aff">1</xref><xref rid="fn1-cm-95-251" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lungulescu</surname><given-names>Cristian Virgil</given-names></name><xref rid="af3-cm-95-251" ref-type="aff">3</xref><xref rid="fn1-cm-95-251" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Volovat</surname><given-names>Simona Ruxandra</given-names></name><xref rid="af4-cm-95-251" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Burz</surname><given-names>Claudia</given-names></name><xref rid="af1-cm-95-251" ref-type="aff">1</xref><xref rid="af5-cm-95-251" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Irimie</surname><given-names>Alexandru</given-names></name><xref rid="af6-cm-95-251" ref-type="aff">6</xref><xref rid="af7-cm-95-251" ref-type="aff">7</xref></contrib></contrib-group><aff id="af1-cm-95-251">
<label>1</label>Department of Medical Oncology, &#x0201c;Prof. Dr. Ion Chiricuta&#x0201d; Institute of Oncology, Cluj-Napoca, Romania</aff><aff id="af2-cm-95-251">
<label>2</label>Department of Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</aff><aff id="af3-cm-95-251">
<label>3</label>Department of Medical Oncology, University of Medicine and Pharmacy, Craiova, Romania</aff><aff id="af4-cm-95-251">
<label>4</label>Department of Medical Oncology, Department of Medical Oncology-Radiotherapy, Grigore T Popa University of Medicine and Pharmacy, Ia&#x00219;i, Romania</aff><aff id="af5-cm-95-251">
<label>5</label>Department of Immunology and Allergology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</aff><aff id="af6-cm-95-251">
<label>6</label>Department of Surgery, &#x0201c;Prof. Dr. Ion Chiricuta&#x0201d; Institute of Oncology, Cluj-Napoca, Romania</aff><aff id="af7-cm-95-251">
<label>7</label>Department of Oncological Surgery and Gynecological Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</aff><author-notes><corresp id="c1-cm-95-251">Address for correspondence: <email>dr.geni@yahoo.co.uk</email></corresp><fn id="fn1-cm-95-251"><label>&#x02020;</label><p>Equal contributions</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>26</day><month>7</month><year>2022</year></pub-date><volume>95</volume><issue>3</issue><fpage>251</fpage><lpage>259</lpage><history><date date-type="received"><day>21</day><month>3</month><year>2021</year></date><date date-type="rev-recd"><day>23</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>10</day><month>3</month><year>2022</year></date></history><permissions><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</license-p></license></permissions><abstract><p>The outcome of colorectal cancer (CRC) can be improved by the identification of prognostic biomarkers. This systematic review of observational cohort and case-control studies was conducted to investigate the role of Endoglin (CD105) in the prognosis of CRC. The databases PubMed, Web of Science, Scopus, and Cochrane CENTRAL were searched to identify the qualified studies using the relevant keywords. After the removal of duplicate articles, the screening was implemented on the titles, abstracts, and potential full-text articles. Afterward, the eligible cohort and case-control studies were identified, and the data were extracted into an Excel datasheet. In total, 11 observational cohort studies and 1 case-control study were identified to be eligible for this systematic review. The majority of the included studies achieved a moderate to high-degree quality according to the Newcastle-Ottawa Scale. Moreover, the eligible studies included a total of 1,400 patients with CRC and mean age of 60 years, the majority of whom were male. Endoglin was observed to be more upregulated in colorectal carcinomas and associated with poor survival outcomes, compared to healthy controls. The levels of Endoglin seem to reflect the degree of cancer invasiveness, therefore predicting dismal prognosis in patients with CRC. Larger and well-designed clinical studies with longer follow-up intervals are needed to investigate the role of Endoglin and its association with cancer metastasis.</p></abstract><kwd-group><kwd>angiogenesis</kwd><kwd>biomarker</kwd><kwd>colorectal cancer</kwd><kwd>Endoglin (CD105)</kwd><kwd>systematic review</kwd><kwd>TGF-&#x003b2; family</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Colorectal cancer (CRC) is considered the third most common cancer worldwide. The overall mortality rate due to CRC was estimated to be 8.9/100.000 in 2018, and the age-standardized incidence rate was high up to 19.7/100.000 [<xref rid="b1-cm-95-251" ref-type="bibr">1</xref>]. It is predicted that 40&#x02013;50% of the newly diagnosed CRC patients will have a relapse despite the recent advances in CRC management. Therefore, there is a need for novel biomarkers that would help in the early detection of this disease [<xref rid="b2-cm-95-251" ref-type="bibr">2</xref>].</p><p>Many commonly used clinical and pathological features help predict the prognosis of CRC. These features include the tumor depth of invasion, tumor grade, lymph node status, and presence of metastasis in the liver [<xref rid="b3-cm-95-251" ref-type="bibr">3</xref>]. However these prognostic parameters often fail to provide accurate prognostic patient stratification. Consequently, novel biomarkers will help predict CRC, thereby fostering better and more accurate treatment protocols for CRC [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>].</p><p>Patients with less advanced stages of CRC are usually treated by curative resection. Nevertheless, subjects with stages II and III CRC typically require postresection adjuvant chemotherapy [<xref rid="b5-cm-95-251" ref-type="bibr">5</xref>]. The value of adjuvant chemotherapy is well-established in stage III patients. However, its role is not consistent in the case of stage II CRC subjects with high-risk features [<xref rid="b6-cm-95-251" ref-type="bibr">6</xref>]. The better identification of CRC prognostic biomarkers would help stratify subgroups of stage II CRC with a higher possibility of recurrence. Therefore, this strategy has the possibility to decrease the burden of CRC patients [<xref rid="b7-cm-95-251" ref-type="bibr">7</xref>].</p><p>Carcinogenesis is chiefly associated with the processes of apoptosis, formation of new blood vessels, and modifications in cellular proliferation [<xref rid="b8-cm-95-251" ref-type="bibr">8</xref>]. Several studies have shown an inverse relationship between the apoptotic index (AI) and survival rates [<xref rid="b9-cm-95-251" ref-type="bibr">9</xref>&#x02013;<xref rid="b11-cm-95-251" ref-type="bibr">11</xref>]. Alcaide et al. [<xref rid="b12-cm-95-251" ref-type="bibr">12</xref>) reported that CRC patients with high AI also had low disease-free and overall survival rates. Angiogenesis plays a vital role not only in CRC growth but also in its progression and metastasis to other organs [<xref rid="b13-cm-95-251" ref-type="bibr">13</xref>]. Vascular endothelial growth factor (VEGF) is associated with the formation of new blood vessels that characterizes the process of angiogenesis in CRC [<xref rid="b14-cm-95-251" ref-type="bibr">14</xref>, <xref rid="b15-cm-95-251" ref-type="bibr">15</xref>]. The process of angiogenesis can be traced and identified using the panendothelial markers, such as the cluster of differentiation 31, cluster of differentiation 34, and CD105 (Endoglin) [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>].</p><p>Endoglin, a coreceptor of the transforming growth factor-beta family, has been proved as a marker of neovascularization in solid malignancies, including CRC [<xref rid="b17-cm-95-251" ref-type="bibr">17</xref>]. Endoglin is excessively expressed in tumor vessels and increases the chances of cancer metastasis [<xref rid="b18-cm-95-251" ref-type="bibr">18</xref>,<xref rid="b19-cm-95-251" ref-type="bibr">19</xref>]. Therefore, a series of studies have revealed the role of Endoglin in the prediction of CRC prognosis and treatment [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>,<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b20-cm-95-251" ref-type="bibr">20</xref>&#x02013;<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]. With this background in mind, the present study aimed to evaluate the prognostic significance of Endoglin expression in patients with CRC using a systematic review approach.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was strictly followed during the current review [<xref rid="b30-cm-95-251" ref-type="bibr">30</xref>]. Moreover, all the study steps were performed in strict accordance with the guidelines of the Cochrane Handbook of Systematic Reviews and Meta-analyses [<xref rid="b31-cm-95-251" ref-type="bibr">31</xref>]. The question behind the research strategy following the Patient, Intervention, Comparison, and Outcome format is whether Endoglin is a prognostic biomarker for CRC patients.</p><sec><title>Literature search strategy</title><p>The databases PubMed, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL), were searched since the inception up to November 2020 using the keywords of (&#x0201c;Endoglin&#x0201d; OR &#x0201c;soluble Endoglin&#x0201d;) OR &#x0201c;CD105&#x0201d; AND (&#x0201c;Colorectal&#x0201d; OR &#x0201c;colon&#x0201d; OR &#x0201c;colonic&#x0201d; OR &#x0201c;rectal&#x0201d; AND &#x0201c;cancer&#x0201d; OR &#x0201c;carcinoma&#x0201d;).</p></sec><sec sec-type="methods"><title>Eligibility criteria and study selection</title><p>All the observational cohort studies (i.e., prospective or retrospective] in addition to case-control studies meeting the following criteria were included in this study. The inclusion criteria were localized and locally-advanced stage of CRC, condition (i.e., level of Endoglin marker), outcomes (i.e., angiogenesis biomarker, survival and remission rates), and study design (i.e., observational cohort and case-control studies). The citations of animal studies, studies published in languages other than English, review articles, editorial letters, and proceedings were excluded from the study.</p></sec><sec sec-type="methods"><title>Screening and study selection</title><p>The study screening and selection processes were initiated after performing the searching step. All the potential records were screened by two reviewers in two phases, namely title/abstract and full-text screening. Additionally, the reference lists of the included studies were screened for relevant citations. Any article causing disagreements between the two reviewers was reevaluated by the third author and discussed in order to achieve a consensus.</p></sec><sec sec-type="methods"><title>Data extraction</title><p>Excel sheets were used to accomplish the data extraction, which was performed by two reviewers. Moreover, the data extraction process was conducted to extract the baseline characteristics of the study participants, risk of bias domains, follow-up period, and survival outcomes. Any disagreement was resolved through a panel discussion.</p></sec><sec><title>Risk of bias assessment</title><p>The Newcastle-Ottawa Scale (NOS) was used for the assessment of the bias within the included studies. The NOS scores are within the range of 0&#x02013;8, and the quality appraisal was freely directed by two reviewers. High-quality studies were scored 6 or higher, while low-quality ones were scored below 6. Any disagreement between the examiners was settled by a conversation with the third specialist.</p><p>It should be mentioned that all the studies included in this systematic review were scored 6 or above. The observational cohort studies were screened regarding the bias domains of selection (i.e., revising the selection process of the studied cohort), comparability (i.e., inter-group comparability of the cohort group), and outcome (i.e., how was the intended outcome measured? was the follow-up period long enough for outcomes to occur?)</p><p>Furthermore, case-control studies were revised in terms of the bias domains of selection (i.e. describing the selection process for case and control groups and establishing a clear definition for cases and controls), comparability (i.e. comparability of the cases and controls based on the design or analysis method), and exposure (i.e. have the cases been already reported with the disease?).</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="results"><title>Search results</title><p>The primary search using the predefined keywords led to the identification of 93 studies. Duplicate references could be omitted using the Endnote software (version X9); accordingly, 48 articles were obtained. In total, 40 papers were eligible for full-text screening after performing the title and abstract screening step. Subsequently, nine retrospective cohort studies, two prospective cohort studies, and one case-control study met the inclusion criteria of the current study and were included in the qualitative synthesis. <xref rid="f1-cm-95-251" ref-type="fig">Figure 1</xref> illustrates the process of study selection.</p></sec><sec sec-type="intro"><title>Patient characteristics</title><p>A total of 1,400 patients with CRC, mean age of 60 years, 55% male and 45% female, were included in the present systematic review;. The mean follow-up period in the included studies was 25 months, ranging from 1 month to 13 years. Regarding the tumor characteristics, the majority of the CRCs in the current review were classified as stages II and III, and most of them were moderately differentiated. Furthermore, 70% of the lesions were in the colon; however, 30% of them were in the rectum. The size of the lesion was within the range of 5&#x02013;10 cm in 62% of the included patients.</p><p>Histopathology results showed a predominance of adenocarcinoma type over mucinous type. In total, 40% of the colorectal tumors in the current study were classified as stage II disease. The mean overall survival reported was 43 months; nevertheless, the mean progression-free survival was 49 months. The majority of the included studies demonstrated that Endoglin overexpression was associated with a poor prognosis of CRC.</p><p>The presence of liver metastasis in the CRC patients was reported in three studies [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>,<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]. In addition, Bal et al. [<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>] and Saad et al. [<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>] demonstrated the incidence of distant metastases from the liver in their patients. Likewise, Li et al. [<xref rid="b28-cm-95-251" ref-type="bibr">28</xref>] and Mitselou et al. [<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>] estimated the incidence rates of cancer-attributed mortality at 91.25% and 17.3%, respectively.</p><p>Out of 12 included studies, eight studies had patients with positive infiltrated lymph nodes [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>,<xref rid="b22-cm-95-251" ref-type="bibr">22</xref>,<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>&#x02013;<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>,<xref rid="b28-cm-95-251" ref-type="bibr">28</xref>,<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]. The rate of positive infiltrated lymph nodes was reported within the range of 22&#x02013;100% in a study performed by Gomceli et al. [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>]. Moreover, the patients had lympho-vascular invasion in four studies [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>,<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>,<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]; nevertheless, two studies only mentioned the occurrence of perineural invasion [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>,<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>]. <xref rid="tI-cm-95-251" ref-type="table">Table I</xref> tabulates the baseline characteristics of the included patients in this systematic review.</p></sec><sec><title>Quality assessment of included studies</title><p>The quality of the included studies was moderate up to high according to the NOS assessment tool. The authors&#x02019; judgment with justifications of the decisions regarding the quality assessment domains is provided in <xref rid="s1-cm-95-251" ref-type="supplementary-material">Supplementary file 1</xref>.</p></sec><sec><title>Role of Endoglin expression in predicting the prognosis of colorectal cancer</title><p>Endoglin was upregulated in tumor tissue, compared to normal tissue, as observed in the studies using control groups with benign colorectal masses or healthy controls [<xref rid="b20-cm-95-251" ref-type="bibr">20</xref>,<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>,<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]. According to Romani et al., [<xref rid="b22-cm-95-251" ref-type="bibr">22</xref>] there was no correlation between the increase in CD105 levels and change in the site of CRC. Mohamed et al. [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>] showed a correlation between high levels of Endoglin and an increase in tumor size. Although this relationship was not proved in the study conducted by Saad et al. [<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>] regarding the histologic types of colorectal carcinoma, high CD105 levels were associated with mucinous histologic type [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>].</p><p>In another study, nonmucinous types of CRC had elevated Endoglin levels [<xref rid="b18-cm-95-251" ref-type="bibr">18</xref>]. High microvascular density (MVD) values given by CD105 were associated with a high incidence of lymph node metastases in two studies [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>, <xref rid="b21-cm-95-251" ref-type="bibr">21</xref>]. Nonetheless, the MVD values had no significant association with lymph node status in another study [<xref rid="b28-cm-95-251" ref-type="bibr">28</xref>].</p><p>Dassoulas et al. used a cut-off value of 7.3% in the MVD for the evaluation of its prognostic value. In the aforementioned study, a group of CRC patients with MVD of higher than 7.3% was reported with significantly lower overall-survival outcomes than the other group [<xref rid="b25-cm-95-251" ref-type="bibr">25</xref>]. Similarly, Gomceli et al. [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>] observed that the levels of soluble Endoglin were not significantly different between the group with local recurrence of CRC and the group with no local recurrence.</p><p>According to a study conducted by Gomceli et al., there was a positive correlation between Dukes&#x02019; stages and plasma Endoglin level detected by sandwich enzyme-linked immunosorbent assay [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>]. Additionally, the MVD assessed by Endoglin levels was significantly associated with a change in Dukes&#x02019; stages, peritoneal infiltration, venous invasion, and tumor relapse in addition to liver and lymph node metastasis in a study performed by Mitselou et al. [<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]. However, Hawinkels et al. revealed no apparent association between serum Endoglin levels and Dukes&#x02019; stages [<xref rid="b27-cm-95-251" ref-type="bibr">27</xref>].</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Our study investigated the value of Endoglin expression in 1,400 CRC patients using a systematic review design, and demonstrated that Endoglin overexpression is associated with poor prognosis in CRC patients. Nine retrospective cohort studies [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b20-cm-95-251" ref-type="bibr">20</xref>&#x02013;<xref rid="b23-cm-95-251" ref-type="bibr">23</xref>,<xref rid="b25-cm-95-251" ref-type="bibr">25</xref>,<xref rid="b27-cm-95-251" ref-type="bibr">27</xref>&#x02013;<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>], two prospective cohort studies [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>,<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>], and one case-control study [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>] were included. Overall, the quality of evidence was graded as moderate for the current systematic review and ranged from moderate to high for the cohort and case-control studies according to the NOS assessment tool. Based on the obtained results of this study, patients with CRC were observed to have upregulated CD105 expression in the tumor blood vessels. High levels of Endoglin were associated with lymph node metastasis, liver metastasis, and distant metastasis, and in some studies, with tumor size [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>,<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>].</p><p>Mohamed et al. [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>] demonstrated poor prognosis in CRC patients with high MVD counts, which were determined using CD105. High Endoglin levels were associated with an advanced stage of CRC, worse histologic type, increased nodal metastasis, higher tumor grade, and increased tumor size [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>]. In addition, the presence of the metastatic foci in the liver of CRC patients was significantly correlated with the level of Endoglin receptors in a study conducted by Saad et al. [<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>]. In contrast, Hawinkels et al. [<xref rid="b27-cm-95-251" ref-type="bibr">27</xref>] showed no statistically significant relationship between CD105 levels in CRC biopsies with tumor size, grade, or histologic grade. Age and gender had no significant effects on the tumor prognosis, nor on cancer behavior.</p><p>In a study carried out by Martins et al., targeting Endoglin was suggested in the form of antiangiogenic therapy to combat CRC [<xref rid="b32-cm-95-251" ref-type="bibr">32</xref>]. Endoglin levels were used for prediction of response to chemotherapeutic agents, radiotherapy, and hormone therapy in laryngeal and breast cancers [<xref rid="b33-cm-95-251" ref-type="bibr">33</xref>&#x02013;<xref rid="b35-cm-95-251" ref-type="bibr">35</xref>]. Uronis et al. observed a statistically significant decrease in the plasma levels of Endoglin while using the chemotherapeutic agent (i.e., bevacizumab) in the treatment of patients with solid tumors [<xref rid="b36-cm-95-251" ref-type="bibr">36</xref>]. A recent study by Nogu&#x000e9;s et al. [<xref rid="b37-cm-95-251" ref-type="bibr">37</xref>] was conducted on 133 CRC patients aiming to assess the value of VEGF and CD105 as diagnostic and prognostic markers for CRC. The results showed that CD105 and VEGF had an essential role in the process of cancer angiogenesis and could be used as biomarkers.</p><p>Although most of the studies concerning Endoglin and cancer have focused on its role as a proangiogenic factor and its utility as an MVD marker, Endoglin has not proven clinical utility yet. On the one hand, using Endoglin in the clinics could be facilitated by the easiness of performing immunohistochemical or molecular techniques. On the other hand, technical issues and the use of different anti-endoglin monoclonal antibodies demonstrate differences in reactivity to endothelial cells and this is likely to result in differences in prognostic and therapeutic efficacy [<xref rid="b38-cm-95-251" ref-type="bibr">38</xref>]. Optimal antibodies should be identified.</p><p>Presently, CRC patient prognostic assessment is based on clinicopathological features and focuses on the cancer stage at the time of diagnosis [<xref rid="b39-cm-95-251" ref-type="bibr">39</xref>]. The main prognostic biomarker used in clinical care is the blood-based carcinoembryonic antigen (CEA) [<xref rid="b40-cm-95-251" ref-type="bibr">40</xref>].</p><p>Mutations in <italic>KRAS/NRAS</italic>, in <italic>BRAF</italic>, along with the mismatch repair gene deficiency microsatellite instability (MSI), are clinically used molecular biomarkers in CRC [<xref rid="b41-cm-95-251" ref-type="bibr">41</xref>]. Most of these markers might inform clinicians of the overall patient prognosis, but they provide limited information for guiding therapeutic decisions, particularly for early-stage CRC. MSI status is a reliable prognostic marker that can identify &#x0201c;high-risk&#x0201d; early-stage CRC patients who lack benefit from adjuvant chemotherapy. Also, MSI has lately emerged as a predictor of immunotherapy-based treatment sensitivity [<xref rid="b42-cm-95-251" ref-type="bibr">42</xref>,<xref rid="b43-cm-95-251" ref-type="bibr">43</xref>]. However, there is a need to find novel predictive biomarkers which may improve these patients&#x02019; management.</p><p>A limitation of our systematic review is the restricted number of studies included. However, this is the reflection of the emerging role of Endoglin as a potential biomarker for CRC management. Other limitations of our systematic review include inconsistences in the design of the evaluated studies including short period of follow-up or lack of serial analysis of CRC patients over time.</p><p>Endoglin represents a promising biomarker to predict prognosis of CRC patients and to be associated with cancer metastasis. Well-designed prospective studies to further identify the role of Endoglin in CRC are warranted. While Endoglin has so far not been analyzed as a therapeutic target in CRC patients, our data point to the fact that this might be a promising approach. Additional preclinical and clinical studies will allow a better understanding of the role of CD105 required to improve treatment of CRC patients.</p></sec><sec><title>Conclusion</title><p>The CD105 levels seem to reflect the degree of cancer invasiveness that can predict the prognosis in patients with colorectal carcinoma. Therefore, larger and well-designed clinical studies with longer follow-up periods to investigate the role of this potential biomarker are required.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><supplementary-material id="s1-cm-95-251" position="float" content-type="local-data"><table-wrap position="anchor" id="tII-cm-95-251"><label>Table SI</label><caption><p>Quality assessment results for included case-control studies.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Study ID</th><th valign="top" align="left" rowspan="1" colspan="1">4- Gomceli 2012 [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>]</th></tr></thead><tbody><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Selection (max. 4</bold>
<sup>*</sup><bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1) Is the case definition adequate?</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2) Representativeness of the cases</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3) Selection of controls</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">4) Definition of controls</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Comparability (max. 2</bold>*<bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1) Comparability of cases and controls based on design or analysis</td><td valign="top" align="left" rowspan="1" colspan="1">**</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"><bold>Exposure (max. 4</bold>*<bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1) Ascertainment of exposure</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2) Similar method of ascertainment for cases and controls</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3) Nonresponse rate</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>8</bold>
</td></tr></tbody></table></table-wrap></supplementary-material><supplementary-material id="s2-cm-95-251" position="float" content-type="local-data"><table-wrap position="anchor" id="tIII-cm-95-251"><label>Table SII</label><caption><p>Quality assessment results for included retrospective cohort studies.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1">Study ID</th><th valign="bottom" align="center" rowspan="1" colspan="1">1-Akagi 2002 [<xref rid="b23-cm-95-251" ref-type="bibr">23</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">2- Bal 2020 [<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">3- Dassoula 2009 [<xref rid="b25-cm-95-251" ref-type="bibr">25</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">5- Hawinkels 2010 [<xref rid="b27-cm-95-251" ref-type="bibr">27</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">6- Li 2003 [<xref rid="b28-cm-95-251" ref-type="bibr">28</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">7- Mitselou 2016 [<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]</th><th valign="bottom" align="center" rowspan="1" colspan="1">8- Mohamed 2017 [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>]</th><th valign="bottom" align="left" rowspan="1" colspan="1">9- Moreira 2011 [<xref rid="b20-cm-95-251" ref-type="bibr">20</xref>]</th><th valign="bottom" align="left" rowspan="1" colspan="1">10- Redondo 2019 [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>]</th><th valign="bottom" align="left" rowspan="1" colspan="1">11- Romani 2006 [<xref rid="b22-cm-95-251" ref-type="bibr">22</xref>]</th><th valign="bottom" align="left" rowspan="1" colspan="1">12- Saad 2003 [<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>]</th></tr></thead><tbody><tr><td colspan="12" valign="top" align="left" rowspan="1"><bold>Selection (max. 4</bold>*<bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Representativeness of exposed cohort</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Selection of nonexposed cohort</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ascertainment of exposure</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Demonstrating that outcome of interest was not present at initiation of study</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td colspan="12" valign="top" align="left" rowspan="1"><bold>Comparability (max. 2</bold>*<bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comparability of cohorts based on design or analysis</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td colspan="12" valign="top" align="left" rowspan="1"><bold>Outcome (max. 5</bold>*<bold>)</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Assessment of outcome</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Was follow-up long enough for outcomes to occur?</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adequacy of follow-up of cohorts</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="center" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td><td valign="top" align="left" rowspan="1" colspan="1">*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Total</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>7</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>6</bold>
</td></tr></tbody></table></table-wrap></supplementary-material></sec></body><back><fn-group><fn id="fn2-cm-95-251"><p><bold>Supplementary file 1.</bold> Quality assessment of included studies.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cm-95-251"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group>
<article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
<source>CA Cancer J Clin</source>
<year>2018</year>
<volume>68</volume>
<fpage>394</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="b2-cm-95-251"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>V</given-names></name><name><surname>Kalita</surname><given-names>J</given-names></name><name><surname>Pal</surname><given-names>M</given-names></name></person-group>
<article-title>Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges</article-title>
<source>Biomed Pharmacother</source>
<year>2017</year>
<volume>87</volume>
<fpage>8</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">28040600</pub-id></element-citation></ref><ref id="b3-cm-95-251"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindmark</surname><given-names>G</given-names></name><name><surname>Gerdin</surname><given-names>B</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>R</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group>
<article-title>Prognostic predictors in colorectal cancer</article-title>
<source>Dis Colon Rectum</source>
<year>1994</year>
<volume>37</volume>
<fpage>1219</fpage>
<lpage>1227</lpage>
<pub-id pub-id-type="pmid">7995147</pub-id></element-citation></ref><ref id="b4-cm-95-251"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Redondo</surname><given-names>M</given-names></name><name><surname>Abitei</surname><given-names>C</given-names></name><name><surname>T&#x000e9;llez</surname><given-names>T</given-names></name><name><surname>F&#x000fa;nez</surname><given-names>R</given-names></name><name><surname>Pereda</surname><given-names>T</given-names></name><name><surname>Rodrigo</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Clinical-pathological characteristics and short-term follow-up associated with proliferation, apoptosis and angiogenesis in a prospective cohort of patients with colorectal tumours</article-title>
<source>Tumour Biol</source>
<year>2019</year>
<volume>42</volume>
<fpage>1010428319835684</fpage>
<pub-id pub-id-type="pmid">30957671</pub-id></element-citation></ref><ref id="b5-cm-95-251"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Kloor</surname><given-names>M</given-names></name><name><surname>Pox</surname><given-names>CP</given-names></name></person-group>
<article-title>Colorectal cancer</article-title>
<source>Lancet</source>
<year>2014</year>
<volume>383</volume>
<fpage>1490</fpage>
<lpage>1502</lpage>
<pub-id pub-id-type="pmid">24225001</pub-id></element-citation></ref><ref id="b6-cm-95-251"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kannarkatt</surname><given-names>J</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Kurniali</surname><given-names>PC</given-names></name><name><surname>Al-Janadi</surname><given-names>A</given-names></name><name><surname>Hrinczenko</surname><given-names>B</given-names></name></person-group>
<article-title>Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma</article-title>
<source>J Oncol Pract</source>
<year>2017</year>
<volume>13</volume>
<fpage>233</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">28399381</pub-id></element-citation></ref><ref id="b7-cm-95-251"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Araghi</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jenkins</surname><given-names>M</given-names></name><name><surname>Brierley</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>E</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Global trends in colorectal cancer mortality: projections to the year 2035</article-title>
<source>Int J Cancer</source>
<year>2019</year>
<volume>144</volume>
<fpage>2992</fpage>
<lpage>3000</lpage>
<pub-id pub-id-type="pmid">30536395</pub-id></element-citation></ref><ref id="b8-cm-95-251"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raskov</surname><given-names>H</given-names></name><name><surname>Pommergaard</surname><given-names>HC</given-names></name><name><surname>Burcharth</surname><given-names>J</given-names></name><name><surname>Rosenberg</surname><given-names>J</given-names></name></person-group>
<article-title>Colorectal carcinogenesis - update and perspectives</article-title>
<source>World J Gastroenterol</source>
<year>2014</year>
<volume>20</volume>
<fpage>18151</fpage>
<lpage>18164</lpage>
<pub-id pub-id-type="pmid">25561783</pub-id></element-citation></ref><ref id="b9-cm-95-251"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bendardaf</surname><given-names>R</given-names></name><name><surname>Ristam&#x000e4;ki</surname><given-names>R</given-names></name><name><surname>Kujari</surname><given-names>H</given-names></name><name><surname>Laine</surname><given-names>J</given-names></name><name><surname>Lamlum</surname><given-names>H</given-names></name><name><surname>Collan</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma</article-title>
<source>Oncology</source>
<year>2003</year>
<volume>64</volume>
<fpage>435</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="pmid">12759543</pub-id></element-citation></ref><ref id="b10-cm-95-251"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hilska</surname><given-names>M</given-names></name><name><surname>Collan</surname><given-names>YU</given-names></name><name><surname>O Laine</surname><given-names>VJ</given-names></name><name><surname>K&#x000f6;ssi</surname><given-names>J</given-names></name><name><surname>Hirsim&#x000e4;ki</surname><given-names>P</given-names></name><name><surname>Laato</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer</article-title>
<source>Dis Colon Rectum</source>
<year>2005</year>
<volume>48</volume>
<fpage>2197</fpage>
<lpage>2208</lpage>
<pub-id pub-id-type="pmid">16400510</pub-id></element-citation></ref><ref id="b11-cm-95-251"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garrity</surname><given-names>MM</given-names></name><name><surname>Burgart</surname><given-names>LJ</given-names></name><name><surname>Mahoney</surname><given-names>MR</given-names></name><name><surname>Windschitl</surname><given-names>HE</given-names></name><name><surname>Salim</surname><given-names>M</given-names></name><name><surname>Wiesenfeld</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes&#x02019; B2 or C colon cancer: a North Central Cancer Treatment Group Study</article-title>
<source>J Clin Oncol</source>
<year>2004</year>
<volume>22</volume>
<fpage>1572</fpage>
<lpage>1582</lpage>
<pub-id pub-id-type="pmid">15117979</pub-id></element-citation></ref><ref id="b12-cm-95-251"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alcaide</surname><given-names>J</given-names></name><name><surname>Funez</surname><given-names>R</given-names></name><name><surname>Rueda</surname><given-names>A</given-names></name><name><surname>Perez-Ruiz</surname><given-names>E</given-names></name><name><surname>Pereda</surname><given-names>T</given-names></name><name><surname>Rodrigo</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>The role and prognostic value of apoptosis in colorectal carcinoma</article-title>
<source>BMC Clin Pathol</source>
<year>2013</year>
<volume>13</volume>
<fpage>24</fpage>
<pub-id pub-id-type="pmid">24106912</pub-id></element-citation></ref><ref id="b13-cm-95-251"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zuazo-Gaztelu</surname><given-names>I</given-names></name><name><surname>Casanovas</surname><given-names>O</given-names></name></person-group>
<article-title>Unraveling the Role of Angiogenesis in Cancer Ecosystems</article-title>
<source>Front Oncol</source>
<year>2018</year>
<volume>8</volume>
<fpage>248</fpage>
<pub-id pub-id-type="pmid">30013950</pub-id></element-citation></ref><ref id="b14-cm-95-251"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chung</surname><given-names>AS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name></person-group>
<article-title>Targeting the tumour vasculature: insights from physiological angiogenesis</article-title>
<source>Nat Rev Cancer</source>
<year>2010</year>
<volume>10</volume>
<fpage>505</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="pmid">20574450</pub-id></element-citation></ref><ref id="b15-cm-95-251"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ellis</surname><given-names>LM</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name></person-group>
<article-title>VEGF-targeted therapy: mechanisms of anti-tumour activity</article-title>
<source>Nat Rev Cancer</source>
<year>2008</year>
<volume>8</volume>
<fpage>579</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="pmid">18596824</pub-id></element-citation></ref><ref id="b16-cm-95-251"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>SY</given-names></name><name><surname>Mohammed</surname><given-names>HL</given-names></name><name><surname>Ibrahim</surname><given-names>HM</given-names></name><name><surname>Mohamed</surname><given-names>EM</given-names></name><name><surname>Salah</surname><given-names>M</given-names></name></person-group>
<article-title>Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases</article-title>
<source>J Gastrointest Cancer</source>
<year>2019</year>
<volume>50</volume>
<fpage>23</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">29110224</pub-id></element-citation></ref><ref id="b17-cm-95-251"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dallas</surname><given-names>NA</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Gray</surname><given-names>MJ</given-names></name><name><surname>Lim</surname><given-names>SJ</given-names></name><etal/></person-group>
<article-title>Endoglin (CD105): a marker of tumor vasculature and potential target for therapy</article-title>
<source>Clin Cancer Res</source>
<year>2008</year>
<volume>14</volume>
<fpage>1931</fpage>
<lpage>1937</lpage>
<pub-id pub-id-type="pmid">18381930</pub-id></element-citation></ref><ref id="b18-cm-95-251"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paauwe</surname><given-names>M</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name><name><surname>Hawinkels</surname><given-names>LJ</given-names></name></person-group>
<article-title>Endoglin for tumor imaging and targeted cancer therapy</article-title>
<source>Expert Opin Ther Targets</source>
<year>2013</year>
<volume>17</volume>
<fpage>421</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="pmid">23327677</pub-id></element-citation></ref><ref id="b19-cm-95-251"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schoonderwoerd</surname><given-names>MJA</given-names></name><name><surname>Goumans</surname><given-names>MTH</given-names></name><name><surname>Hawinkels</surname><given-names>LJAC</given-names></name></person-group>
<article-title>Endoglin: Beyond the Endothelium</article-title>
<source>Biomolecules</source>
<year>2020</year>
<volume>10</volume>
<fpage>289</fpage>
</element-citation></ref><ref id="b20-cm-95-251"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moreira</surname><given-names>LR</given-names></name><name><surname>Schenka</surname><given-names>AA</given-names></name><name><surname>Latuf-Filho</surname><given-names>P</given-names></name><name><surname>Penn&#x000e1;</surname><given-names>AL</given-names></name><name><surname>Lima</surname><given-names>CS</given-names></name><name><surname>Soares</surname><given-names>FA</given-names></name><etal/></person-group>
<article-title>Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors</article-title>
<source>Tumour Biol</source>
<year>2011</year>
<volume>32</volume>
<fpage>527</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">21222066</pub-id></element-citation></ref><ref id="b21-cm-95-251"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saad</surname><given-names>RS</given-names></name><name><surname>Liu</surname><given-names>YL</given-names></name><name><surname>Nathan</surname><given-names>G</given-names></name><name><surname>Celebrezze</surname><given-names>J</given-names></name><name><surname>Medich</surname><given-names>D</given-names></name><name><surname>Silverman</surname><given-names>JF</given-names></name></person-group>
<article-title>Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer</article-title>
<source>Mod Pathol</source>
<year>2004</year>
<volume>17</volume>
<fpage>197</fpage>
<lpage>203</lpage>
<pub-id pub-id-type="pmid">14657950</pub-id></element-citation></ref><ref id="b22-cm-95-251"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romani</surname><given-names>AA</given-names></name><name><surname>Borghetti</surname><given-names>AF</given-names></name><name><surname>Del Rio</surname><given-names>P</given-names></name><name><surname>Sianesi</surname><given-names>M</given-names></name><name><surname>Soliani</surname><given-names>P</given-names></name></person-group>
<article-title>The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count</article-title>
<source>J Surg Oncol</source>
<year>2006</year>
<volume>93</volume>
<fpage>446</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">16615157</pub-id></element-citation></ref><ref id="b23-cm-95-251"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Akagi</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Sumiyoshi</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>J</given-names></name><name><surname>Miyazaki</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development</article-title>
<source>Surgery</source>
<year>2002</year>
<volume>131</volume>
<issue>1 Suppl</issue>
<fpage>S109</fpage>
<lpage>S113</lpage>
<pub-id pub-id-type="pmid">11821796</pub-id></element-citation></ref><ref id="b24-cm-95-251"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bal</surname><given-names>O</given-names></name><name><surname>Ekinci</surname><given-names>AS</given-names></name><name><surname>Dogan</surname><given-names>M</given-names></name><name><surname>Atay</surname><given-names>C</given-names></name><name><surname>Demirci</surname><given-names>A</given-names></name><name><surname>Oksuzoglu</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The prognostic and predictive significance of plasma type 1 plasminogen activator inhibitor and endoglin in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy</article-title>
<source>J Cancer Res Ther</source>
<year>2019</year>
<volume>15</volume>
<fpage>48</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">30880754</pub-id></element-citation></ref><ref id="b25-cm-95-251"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dassoulas</surname><given-names>K</given-names></name><name><surname>Gazouli</surname><given-names>M</given-names></name><name><surname>Theodoropoulos</surname><given-names>G</given-names></name><name><surname>Christoni</surname><given-names>Z</given-names></name><name><surname>Rizos</surname><given-names>S</given-names></name><name><surname>Zisi-Serbetzoglou</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Vascular endothelial growth factor and endoglin expression in colorectal cancer</article-title>
<source>J Cancer Res Clin Oncol</source>
<year>2010</year>
<volume>136</volume>
<fpage>703</fpage>
<lpage>708</lpage>
<pub-id pub-id-type="pmid">19890661</pub-id></element-citation></ref><ref id="b26-cm-95-251"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gomceli</surname><given-names>I</given-names></name><name><surname>Tez</surname><given-names>M</given-names></name><name><surname>Bostanci</surname><given-names>EB</given-names></name><name><surname>Turhan</surname><given-names>N</given-names></name><name><surname>Kemik</surname><given-names>AS</given-names></name><name><surname>Akoglu</surname><given-names>M</given-names></name></person-group>
<article-title>Preoperative serum levels of soluble endoglin for prediction of recurrence in stage III colorectal cancer patients</article-title>
<source>Acta Medica (Hradec Kralove)</source>
<year>2012</year>
<volume>55</volume>
<fpage>74</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">23101269</pub-id></element-citation></ref><ref id="b27-cm-95-251"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hawinkels</surname><given-names>LJ</given-names></name><name><surname>Kuiper</surname><given-names>P</given-names></name><name><surname>Wiercinska</surname><given-names>E</given-names></name><name><surname>Verspaget</surname><given-names>HW</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Pardali</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis</article-title>
<source>Cancer Res</source>
<year>2010</year>
<volume>70</volume>
<fpage>4141</fpage>
<lpage>4150</lpage>
<pub-id pub-id-type="pmid">20424116</pub-id></element-citation></ref><ref id="b28-cm-95-251"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Gardy</surname><given-names>R</given-names></name><name><surname>Seon</surname><given-names>BK</given-names></name><name><surname>Duff</surname><given-names>SE</given-names></name><name><surname>Abdalla</surname><given-names>S</given-names></name><name><surname>Renehan</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis</article-title>
<source>Br J Cancer</source>
<year>2003</year>
<volume>88</volume>
<fpage>1424</fpage>
<lpage>1431</lpage>
<pub-id pub-id-type="pmid">12778073</pub-id></element-citation></ref><ref id="b29-cm-95-251"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mitselou</surname><given-names>A</given-names></name><name><surname>Galani</surname><given-names>V</given-names></name><name><surname>Skoufi</surname><given-names>U</given-names></name><name><surname>Arvanitis</surname><given-names>DL</given-names></name><name><surname>Lampri</surname><given-names>E</given-names></name><name><surname>Ioachim</surname><given-names>E</given-names></name></person-group>
<article-title>Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/&#x003b2;-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer</article-title>
<source>Anticancer Res</source>
<year>2016</year>
<volume>36</volume>
<fpage>2271</fpage>
<lpage>2280</lpage>
<pub-id pub-id-type="pmid">27127133</pub-id></element-citation></ref><ref id="b30-cm-95-251"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group>
<collab>PRISMA Group</collab>
<article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>
<source>PLoS Med</source>
<year>2009</year>
<volume>6</volume>
<fpage>e1000097</fpage>
<pub-id pub-id-type="pmid">19621072</pub-id></element-citation></ref><ref id="b31-cm-95-251"><label>31</label><element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Chandler</surname><given-names>J</given-names></name><name><surname>Cumpston</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Page</surname><given-names>MJ</given-names></name><etal/></person-group>
<source>Cochrane handbook for systematic reviews of interventions</source>
<publisher-name>John Wiley &#x00026; Sons</publisher-name>
<year>2019</year>
</element-citation></ref><ref id="b32-cm-95-251"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martins</surname><given-names>SF</given-names></name><name><surname>Reis</surname><given-names>RM</given-names></name><name><surname>Rodrigues</surname><given-names>AM</given-names></name><name><surname>Baltazar</surname><given-names>F</given-names></name><name><surname>Filho</surname><given-names>AL</given-names></name></person-group>
<article-title>Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies</article-title>
<source>World J Clin Oncol</source>
<year>2011</year>
<volume>2</volume>
<fpage>272</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">21773077</pub-id></element-citation></ref><ref id="b33-cm-95-251"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marioni</surname><given-names>G</given-names></name><name><surname>Ottaviano</surname><given-names>G</given-names></name><name><surname>Lionello</surname><given-names>M</given-names></name><name><surname>Fasanaro</surname><given-names>E</given-names></name><name><surname>Staffieri</surname><given-names>C</given-names></name><name><surname>Giacomelli</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>A panel of biomarkers for predicting response to postoperative RT for laryngeal cancer?</article-title>
<source>Am J Otolaryngol</source>
<year>2014</year>
<volume>35</volume>
<fpage>771</fpage>
<lpage>778</lpage>
<pub-id pub-id-type="pmid">25064017</pub-id></element-citation></ref><ref id="b34-cm-95-251"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vo</surname><given-names>MN</given-names></name><name><surname>Evans</surname><given-names>M</given-names></name><name><surname>Leitzel</surname><given-names>K</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Demers</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy</article-title>
<source>Breast Cancer Res Treat</source>
<year>2010</year>
<volume>119</volume>
<fpage>767</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="pmid">19115106</pub-id></element-citation></ref><ref id="b35-cm-95-251"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beresford</surname><given-names>MJ</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Ah-See</surname><given-names>M</given-names></name><name><surname>Daley</surname><given-names>F</given-names></name><name><surname>Padhani</surname><given-names>AR</given-names></name><name><surname>Makris</surname><given-names>A</given-names></name></person-group>
<article-title>The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer</article-title>
<source>Br J Cancer</source>
<year>2006</year>
<volume>95</volume>
<fpage>1683</fpage>
<lpage>1688</lpage>
<pub-id pub-id-type="pmid">17160082</pub-id></element-citation></ref><ref id="b36-cm-95-251"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uronis</surname><given-names>HE</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Bendell</surname><given-names>JC</given-names></name><name><surname>Howard</surname><given-names>L</given-names></name><name><surname>Ready</surname><given-names>NA</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><etal/></person-group>
<article-title>A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors</article-title>
<source>Cancer Chemother Pharmacol</source>
<year>2015</year>
<volume>75</volume>
<fpage>343</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="pmid">25527204</pub-id></element-citation></ref><ref id="b37-cm-95-251"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nogu&#x000e9;s</surname><given-names>A</given-names></name><name><surname>Gallardo-Vara</surname><given-names>E</given-names></name><name><surname>Zafra</surname><given-names>MP</given-names></name><name><surname>Mate</surname><given-names>P</given-names></name><name><surname>Marijuan</surname><given-names>JL</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer</article-title>
<source>World J Surg Oncol</source>
<year>2020</year>
<volume>18</volume>
<fpage>99</fpage>
<pub-id pub-id-type="pmid">32434528</pub-id></element-citation></ref><ref id="b38-cm-95-251"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nassiri</surname><given-names>F</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Rotondo</surname><given-names>F</given-names></name><name><surname>Fazio</surname><given-names>A</given-names></name><name><surname>Yousef</surname><given-names>GM</given-names></name><etal/></person-group>
<article-title>Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy</article-title>
<source>Anticancer Res</source>
<year>2011</year>
<volume>31</volume>
<fpage>2283</fpage>
<lpage>2290</lpage>
<pub-id pub-id-type="pmid">21737653</pub-id></element-citation></ref><ref id="b39-cm-95-251"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahar</surname><given-names>AL</given-names></name><name><surname>Compton</surname><given-names>C</given-names></name><name><surname>Halabi</surname><given-names>S</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Weiser</surname><given-names>MR</given-names></name><name><surname>Groome</surname><given-names>PA</given-names></name></person-group>
<article-title>Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes</article-title>
<source>J Surg Oncol</source>
<year>2017</year>
<volume>116</volume>
<fpage>969</fpage>
<lpage>982</lpage>
<pub-id pub-id-type="pmid">28767139</pub-id></element-citation></ref><ref id="b40-cm-95-251"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alves Martins</surname><given-names>BA</given-names></name><name><surname>de Bulh&#x000f5;es</surname><given-names>GF</given-names></name><name><surname>Cavalcanti</surname><given-names>IN</given-names></name><name><surname>Martins</surname><given-names>MM</given-names></name><name><surname>de Oliveira</surname><given-names>PG</given-names></name><name><surname>Martins</surname><given-names>AMA</given-names></name></person-group>
<article-title>Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research</article-title>
<source>Front Oncol</source>
<year>2019</year>
<volume>9</volume>
<fpage>1284</fpage>
<pub-id pub-id-type="pmid">31828035</pub-id></element-citation></ref><ref id="b41-cm-95-251"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koncina</surname><given-names>E</given-names></name><name><surname>Haan</surname><given-names>S</given-names></name><name><surname>Rauh</surname><given-names>S</given-names></name><name><surname>Letellier</surname><given-names>E</given-names></name></person-group>
<article-title>Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges</article-title>
<source>Cancers (Basel)</source>
<year>2020</year>
<volume>12</volume>
<fpage>319</fpage>
</element-citation></ref><ref id="b42-cm-95-251"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Argil&#x000e9;s</surname><given-names>G</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><name><surname>Hochhauser</surname><given-names>D</given-names></name><name><surname>Salazar</surname><given-names>R</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title>
<source>Ann Oncol</source>
<year>2020</year>
<volume>31</volume>
<fpage>1291</fpage>
<lpage>1305</lpage>
<pub-id pub-id-type="pmid">32702383</pub-id></element-citation></ref><ref id="b43-cm-95-251"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Falco</surname><given-names>V</given-names></name><name><surname>Napolitano</surname><given-names>S</given-names></name><name><surname>Rosell&#x000f3;</surname><given-names>S</given-names></name><name><surname>Huerta</surname><given-names>M</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Ciardiello</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>How we treat metastatic colorectal cancer</article-title>
<source>ESMO Open</source>
<year>2020</year>
<volume>4</volume>
<issue>Suppl 2</issue>
<fpage>e000813</fpage>
<pub-id pub-id-type="pmid">32817137</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="f1-cm-95-251"><label>Figure 1</label><caption><p>PRISMA flow chart of the study selection.</p></caption><graphic xlink:href="cm-95-251f1" position="float"/></fig><table-wrap position="float" id="tI-cm-95-251"><label>Table I</label><caption><p>Baseline characteristics of included patients.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Reference</th><th valign="middle" align="left" rowspan="1" colspan="1">Country</th><th valign="middle" align="left" rowspan="1" colspan="1">Study population</th><th valign="middle" align="left" rowspan="1" colspan="1">Study design</th><th valign="middle" align="left" rowspan="1" colspan="1">Age (mean &#x000b1; standard deviation)</th><th valign="middle" align="left" rowspan="1" colspan="1">Characteristics of patients</th><th valign="middle" align="left" rowspan="1" colspan="1">Endoglin evaluation</th><th valign="middle" align="left" rowspan="1" colspan="1">Overall survival (month)</th><th valign="middle" align="left" rowspan="1" colspan="1">Progression-free survival (month)</th><th valign="middle" align="left" rowspan="1" colspan="1">Outcome</th><th valign="middle" align="left" rowspan="1" colspan="1">Summary of findings</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Akagi et al. 2002 [<xref rid="b23-cm-95-251" ref-type="bibr">23</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Japan</td><td valign="middle" align="left" rowspan="1" colspan="1">74</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoscopically resected colorectal adenomas<break/>T1, T2 surgically resected colorectal adenocarcinoma</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE<xref rid="tfn2-cm-95-251" ref-type="table-fn">2</xref></td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin value in microvessel quantification in CRC carcinogenesis</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin is an effective marker in the assessment of angiogenesis in CRC development</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Bal et al. 2019 [<xref rid="b24-cm-95-251" ref-type="bibr">24</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Turkey</td><td valign="middle" align="left" rowspan="1" colspan="1">47</td><td valign="middle" align="left" rowspan="1" colspan="1">Prospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">58.5&#x000b1;9.6</td><td valign="middle" align="left" rowspan="1" colspan="1">Metastatic CRC<xref rid="tfn1-cm-95-251" ref-type="table-fn">1</xref> patients treated with bevacizumab containing chemotherapy</td><td valign="middle" align="left" rowspan="1" colspan="1">Serum</td><td valign="middle" align="left" rowspan="1" colspan="1">Mean: 20.8 Standard error: 1.5<break/>95% confidence interval: 17.8&#x02013;23.7</td><td valign="middle" align="left" rowspan="1" colspan="1">Mean: 17.5 Standard error: 1.3<break/>95% confidence interval: 14.9&#x02013;20</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin prognostic value for bevacizumab treatment response</td><td valign="middle" align="left" rowspan="1" colspan="1">No significance in prediction of treatment response (We checked the data - all are compliant. The information is expressed as non-median averages - median only for follow-up - for OS, PFS mean - even in the Kaplan graphs - tab = mean)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Dassoulas et al. 2010 [<xref rid="b25-cm-95-251" ref-type="bibr">25</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Greece</td><td valign="middle" align="left" rowspan="1" colspan="1">99</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">69.34&#x000b1;11.59</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Association between Endoglin and VEGF<xref rid="tfn3-cm-95-251" ref-type="table-fn">3</xref> expression and correlation with clinico-pathological characteristics and survival</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin and VEGF were positively correlated; increased Endoglin MVD<xref rid="tfn4-cm-95-251" ref-type="table-fn">4</xref> was linked to decreased overall survival</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gomceli et al. 2012 [<xref rid="b26-cm-95-251" ref-type="bibr">26</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Turkey</td><td valign="middle" align="left" rowspan="1" colspan="1">80</td><td valign="middle" align="left" rowspan="1" colspan="1">Case-control study</td><td valign="middle" align="left" rowspan="1" colspan="1">62</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated stage III CRC patients, healthy control group</td><td valign="middle" align="left" rowspan="1" colspan="1">Serum</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Predictive value of preoperative Endoglin levels for recurrence in stage III CRC</td><td valign="middle" align="left" rowspan="1" colspan="1">No relation could be observed between Endoglin levels and risk of recurrence nor with any clinico-pathological characteristics</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hawinkels et al. 2010 [<xref rid="b27-cm-95-251" ref-type="bibr">27</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Netherlands</td><td valign="middle" align="left" rowspan="1" colspan="1">48</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">.</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients, healthy control group</td><td valign="middle" align="left" rowspan="1" colspan="1">Plasma</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Role of soluble Endoglin in angiogenesis</td><td valign="middle" align="left" rowspan="1" colspan="1">Soluble Endoglin has antiangiogenic properties and inhibits VEGF induced angiogenesis</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Li et al. 2003 [<xref rid="b28-cm-95-251" ref-type="bibr">28</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">UK</td><td valign="middle" align="left" rowspan="1" colspan="1">111</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">69.5</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">Median: 67.2<break/>Range: 3.6&#x02013;96</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Prognostic value of Endoglin stained MVD</td><td valign="middle" align="left" rowspan="1" colspan="1">High Endoglin-stained MVD predicts poor survival</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Mitselou et al. 2016 [<xref rid="b29-cm-95-251" ref-type="bibr">29</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Greece</td><td valign="middle" align="left" rowspan="1" colspan="1">69</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">64.58&#x000b1;7.2</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Association between Syndecan-1, E-cadherin/&#x003b2;-catenin, platelet-derived endothelial cell adhesion molecule-1, and Endoglin</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin expression was linked to E-cadherin, &#x003b2;-catenin, and syndecan-1; Endoglin MVD was associated with Dukes&#x02019; stage, vascular invasion, lymph node and liver metastasis, disease recurrence, and worse survival</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Mohamed et al. 2019 [<xref rid="b16-cm-95-251" ref-type="bibr">16</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Egypt</td><td valign="middle" align="left" rowspan="1" colspan="1">50</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">50</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Prognostic value of Endoglin MVD</td><td valign="middle" align="left" rowspan="1" colspan="1">High Endoglin MVD was associated with tumor size, high grade, lymph node invasion, advanced stage, and poor survival</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Moreira et al. 2011 [<xref rid="b20-cm-95-251" ref-type="bibr">20</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Brazil</td><td valign="middle" align="left" rowspan="1" colspan="1">60</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">60</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Role of angio- and lymphangio- vascular density in CRC prognosis</td><td valign="middle" align="left" rowspan="1" colspan="1">No prognostic value for Endoglin MVD</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Redondo et al. 2019 [<xref rid="b4-cm-95-251" ref-type="bibr">4</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Spain</td><td valign="middle" align="left" rowspan="1" colspan="1">487</td><td valign="middle" align="left" rowspan="1" colspan="1">Prospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">68.1</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">Mean: 38.5<break/>95% confidence interval: 36.4&#x02013;40.6</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Prognostic value of Endoglin in 2-year survival and clinicopathological features</td><td valign="middle" align="left" rowspan="1" colspan="1">No association between Endoglin expression and short-term survival or clinicopathological features except [Only MEAN) age</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Romani et al. 2006 [<xref rid="b22-cm-95-251" ref-type="bibr">22</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">Italy</td><td valign="middle" align="left" rowspan="1" colspan="1">125</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">65.6</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">Mean: 45.3 Standard deviation: 5.42</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Role of Endoglin in angiogenesis in CRC metastasis</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin vessel count may detect patients at risk for metastatic disease</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Saad et al. 2004 [<xref rid="b21-cm-95-251" ref-type="bibr">21</xref>]</td><td valign="middle" align="left" rowspan="1" colspan="1">USA</td><td valign="middle" align="left" rowspan="1" colspan="1">150</td><td valign="middle" align="left" rowspan="1" colspan="1">Retrospective cohort</td><td valign="middle" align="left" rowspan="1" colspan="1">72&#x000b1;9</td><td valign="middle" align="left" rowspan="1" colspan="1">Surgically treated CRC patients</td><td valign="middle" align="left" rowspan="1" colspan="1">FFPE</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">-</td><td valign="middle" align="left" rowspan="1" colspan="1">Comparison of CD31 and Endoglin as a marker for MVD; Endoglin prognostic value in CRC</td><td valign="middle" align="left" rowspan="1" colspan="1">Endoglin was superior to CD31 in evaluation of MVD; Endoglin MVD was linked to angiolymphatic invasion, lymph node, and liver metastases</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cm-95-251"><label>1</label><p>Colorectal cancer;</p></fn><fn id="tfn2-cm-95-251"><label>2</label><p>Formalin-fixed and paraffin-embedded;</p></fn><fn id="tfn3-cm-95-251"><label>3</label><p>Vascular endothelial growth factor;</p></fn><fn id="tfn4-cm-95-251"><label>4</label><p>Microvascular density</p></fn></table-wrap-foot></table-wrap></floats-group></article>
